Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 4/2020

01-12-2020 | Fatty Liver | Fatty Liver Disease (D Halegoua-De Marzio, Section Editor)

National and Global Ethnicity Differences in Non-alcoholic Fatty Liver Disease

Authors: Anita Krishnarao, Carmi S. Punzalan

Published in: Current Hepatology Reports | Issue 4/2020

Login to get access

Abstract

Purpose of Review

Non-alcoholic fatty liver disease (NAFLD) remains a leading cause of chronic liver disease and a growing public health concern. This review aims to examine the reported national and international ethnicity differences in NAFLD.

Recent Findings

Prior studies have shown that Latino populations were disproportionately affected by both NAFLD and non-alcoholic steatohepatitis (NASH) in the USA compared to non-Latino White populations. Black and Asian Americans are reported to have a lower prevalence of NAFLD. Contributing factors for ethnic disparities may include socioeconomic factors, body fat distribution trends, genetic factors, and prevalence of associated disease states.

Summary

Ethnic differences in NAFLD have been identified in the USA and internationally. The Latino population seems to have the highest prevalence of NAFLD in the USA, but ethnicity-related differences in disease characteristics and outcomes have yet to be fully elucidated.
Literature
1.
Weston SR, Leyden W, Murphy R, Bass NM, Bell BP, Manos MM, et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology. 2005;41(2):372–9.CrossRef
2.
Schwimmer JB, McGreal N, Deutsch R, Finegold MJ, Lavine JE. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics. 2005;115(5):561–5.CrossRef
3.
•• Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors, and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20. This review represents one of the most recent summaries of genetic and environmental risk factors for NAFLD and NASH and their variable distribution across different ethnicities and countries worldwide.CrossRef
4.
Saab S, Manne V, Nieto J, Schwimmer JB, Chalasani NP. Nonalcoholic fatty liver disease in Latinos. Clin Gastroenterol Hepatol. 2016;14:5–12.CrossRef
5.
Caldwell SH, Harris DM, Patrie JT, Hespenheide EE. Is NASH underdiagnosed among African Americans? Am J Gastroenterol. 2002;97:1496–500.CrossRef
6.
• Golabi P, Paik J, Hwang JP, Wang S, Lee HM, Younossi ZM. Prevalence and outcomes of non-alcoholic fatty liver disease (NAFLD) among Asian American adults in the United States. Liver Int. 2019;39:748–57. https://​doi.​org/​10.​1111/​liv.​14038. This study is one of the few that analyzes NAFLD prevalence and risk factors in Asian Americans.
7.
8.
Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313:2263–73.CrossRef
9.
Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine. 2012;91:319–27.
10.
•• Rich NE, Oji S, Mufti AR, Browning JD, Parikh ND, Odewole M, et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and Meta-analysis. Clin Gastroenterol Hepatol. 2018;16:198–210. This study is a unique meta-analysis that helps characterize ethnic disparities in NAFLD prevalence and severity based on recent population-based studies in the US.CrossRef
11.
Fleischman MW, Budoff M, Zeb I, Li D, Foster T. NAFLD prevalence differs among Hispanic subgroups: the multi-ethnic study of atherosclerosis. World J Gastroenterol. 2014;20:4987–93.CrossRef
12.
Lomonaco R, Ortiz-Lopez C, Orsak B, Finch J, Webb A, Bril F, et al. Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. Hepatology. 2011;54:837–45.
13.
Bambha K, Belt P, Abraham M, Wilson LA, Pabst M, Ferrell L, et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology. 2012;55:769–80.
14.
Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–95.
15.
Pan JJ, Fallon MB. Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol. 2014;6:274–83.CrossRef
16.
Guerrero R, Vega GL, Grundy SM, Browning JD. Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology. 2009;49:791–801.CrossRef
17.
Bril F, Portillo-Sanchez P, Liu IC, Kalavalapalli S, Dayton K, Cusi K. Clinical and histologic characterization of nonalcoholic steatohepatitis in African American patients. Diabetes Care. 2018;41:187–92.CrossRef
18.
Setiawan VW, Stram DO, Porcel J, Lu SC, Le Marchand L, Noureddin M. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the multiethnic cohort. Hepatology. 2016;64:1969–77.CrossRef
19.
Wong RJ, Ahmed A. Obesity and non-alcoholic fatty liver disease: disparate associations among Asian populations. World J Hepatol. 2014;6:263–73.CrossRef
20.
21.
Petersen KF, Dufour S, Feng J, Befroy D, Dziura J, Dalla Man C, et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci. 2006;103:18273–7.
22.
23.
Scaglione S, Kliethermes S, Cao G, Shoham D, Durazo R, Luke A, et al. The epidemiology of cirrhosis in the United States. J Clin Gastroenterol. 2015;49:690–6.
24.
Bialek SR, Redd JT, Lynch A, Vogt T, Lewis S, Wilson C, et al. Chronic liver disease among two American Indian patient populations in the southwestern United States, 2000-2003. J Clin Gastroenterol. 2008;42:849–54.
25.
Noureddin M, Zelber-Sagi S, Wilkens LR, Porcel J, Boushey CJ, Le Marchand L, et al. Diet associations with nonalcoholic fatty liver disease and an ethnically diverse populations: the multiethnic cohort. Hepatology. 2020;71:1940–52.CrossRef
26.
Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461–5.
27.
Wagenknecht LE, Palmer ND, Bowden DW, Rotter JI, Norris JM, Ziegler J, et al. Association of PNPLA3 with non-alcoholic fatty liver disease in a minority cohort: the Insulin Resistance Atherosclerosis Family Study. Liver Int. 2011;31:412–6.
28.
Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011;53:1883–94.CrossRef
29.
Browning JD. Common genetic variants and nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2013;11:1191–3.CrossRef
30.
Chow EA, Foster H, Gonzalez V, McIver L. The disparate impact of diabetes on racial/ethnic minority populations. Clin Diabetes. 2012;30:130–3.CrossRef
31.
Dickman SL, Himmelstein DU, Woolhandler S. Inequality and the health-care system in the USA. Lancet. 2017;389:1431–41.CrossRef
32.
Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389:1453–63.CrossRef
33.
Noureddin M, Yates KP, Vaughn IA, Neuschwander-Tetri BA, Sanyal AJ, McCullough A, et al. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology. 2013;58(5):1644–54.
34.
Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956–65.CrossRef
35.
Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394:2184–96.CrossRef
36.
Wilder J, Saraswathula A, Hasselblad V, Muir A. A systematic review of race and ethnicity in hepatitis C clinical trial enrollment. J Natl Med Assoc. 2016;108:24–9.CrossRef
37.
Geller SE, Koch AR, Roesch P, Filut A, Hallgren E, Carnes M. The more things change, the more they stay the same: a study to evaluate compliance with inclusion and assessment of women and minorities in randomized controlled trials. Acad Med. 2018;93:630.CrossRef
38.
Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–55.
39.
Eshraghian A. High prevalence of nonalcoholic fatty liver disease in the Middle East: lifestyle and dietary habits. Hepatology. 2017;65:1077.CrossRef
40.
Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330–44.CrossRef
41.
Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686–90.CrossRef
42.
Younes R, Bugianesi E. NASH in lean individuals. Semin Liver Dis. 2019;39(1):86–95.CrossRef
43.
Neukam K, Sanjay BS, Rodger A, Oben J, Nirmal D, Jain A, et al. High prevalence of non-alcoholic fatty liver disease (NAFLD) among Gujarati Indians in North London: a population based study. Clin Lipidol. 2017;12:33–9.
44.
Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67:862–73.CrossRef
45.
Yousef MH, Juboori AA, Albarrak AA, Ibdah JA, Tahan V. Fatty liver without a large “belly”: magnified review of non-alcoholic fatty liver disease in non-obese patients. World J Gastrointest Pathophysiol. 2017;8:100–7.CrossRef
46.
Olusanya TO, Lesi OA, Adeyomoye AA, Fasanmade OA. Non alcoholic fatty liver disease in a Nigerian population with type II diabetes mellitus. Pan Afr Med J. 2016;24:20.CrossRef
47.
Metadata
Title
National and Global Ethnicity Differences in Non-alcoholic Fatty Liver Disease
Authors
Anita Krishnarao
Carmi S. Punzalan
Publication date
01-12-2020
Publisher
Springer US
Keyword
Fatty Liver
Published in
Current Hepatology Reports / Issue 4/2020
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-020-00552-8

Other articles of this Issue 4/2020

Current Hepatology Reports 4/2020 Go to the issue

Fatty Liver Disease (D Halegoua-DeMarzio, Section Editor)

The Role of Gut Microbiome-Targeted Therapy in Nonalcoholic Fatty Liver Disease

Hepatitis B (JK Lim, Section Editor)

The Role of RNA Interference in Functional Cure Strategies for Chronic Hepatitis B

Hepatic Cancer (N Parikh, Section Editor)

A Contemporary Approach to Diagnosis and Treatment of Combined Hepatocellular-Cholangiocarcinoma

Hepatitis B (JK Lim, Section Editor)

Diagnosis and Management of Occult Hepatitis B Infection

Management of Cirrhotic Patient (A Cardenas and P Tandon, Section Editors)

Spontaneous Bacterial Peritonitis and Secondary Bacterial Peritonitis—a Comprehensive Review

Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)

Medication Non-adherence among Liver Transplant Recipients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits